Literature DB >> 8903382

A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group.

R E Poupon1, P M Huet, R Poupon, A M Bonnand, J T Nhieu, E S Zafrani.   

Abstract

The efficacy of colchicine combined with ursodeoxycholic acid (UDCA) and UDCA alone in the treatment of patients with nonadvanced primary biliary cirrhosis (PBC) was evaluated in a 2-year controlled study. Seventy-four patients with PBC who had been treated previously with UDCA (at least 8 months) but still had abnormal liver test results, especially elevated alkaline phosphatase activity, were randomized to be administered colchicine (1 mg/d, 5 days per week) (n = 37) or a placebo (n = 37). In addition, the patients were treated with UDCA (13-15 mg x kg(-1) x day(-1)). The patients underwent clinical examination and liver tests every 6 months and upper endoscopy and liver biopsy at entry and at 2 years. Procollagen type III aminoterminal peptide (PIIINP), hyaluronic acid, and sulfobromophthalein (BSP) elimination kinetics were determined at entry and after 2 years. After 2 years of treatment, relative to UDCA, colchicine combined with UDCA did not significantly improve symptoms, laboratory findings (serum bilirubin level, alkaline phosphatase and alanine transaminase [ALT] activities, immunoglobulin [Ig] M level), serum markers of fibrosis, or histological features, except lobular inflammation. Colchicine did tend to slightly reduce the progression of esophageal varices; however, the difference was not significant. BSP elimination kinetics (45-minute retention percentage) was significantly improved when treated with colchicine. During the 2-year study, the only clinical complications were variceal bleeding in one patient administered colchicine and two administered the placebo. Two patients died from nonliver causes. One severe adverse effect (peripheral neuromyopathy) was observed in a colchicine-treated patient. In conclusion, this study suggests that colchicine appears to provide a slight advantage relative to UDCA alone in patients with nonadvanced PBC.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8903382     DOI: 10.1002/hep.510240520

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  17 in total

Review 1.  Primary biliary cirrhosis: new perspectives in diagnosis and treatment.

Authors:  M I Prince; D E Jones
Journal:  Postgrad Med J       Date:  2000-04       Impact factor: 2.401

2.  Treatment Options for Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis.

Authors:  Cynthia Levy; Keith D. Lindor
Journal:  Curr Treat Options Gastroenterol       Date:  2003-04

Review 3.  Delivery and targeting of miRNAs for treating liver fibrosis.

Authors:  Virender Kumar; Ram I Mahato
Journal:  Pharm Res       Date:  2014-09-04       Impact factor: 4.200

Review 4.  Ursodeoxycholic acid for primary biliary cirrhosis.

Authors:  Jelena S Rudic; Goran Poropat; Miodrag N Krstic; Goran Bjelakovic; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

Review 5.  Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.

Authors:  Christian Rust; Ulrich Beuers
Journal:  Clin Rev Allergy Immunol       Date:  2005-04       Impact factor: 8.667

Review 6.  [Primary biliary liver cirrhosis and overlap syndrome. Diagnosis and therapy].

Authors:  C P Strassburg; M P Manns
Journal:  Internist (Berl)       Date:  2004-01       Impact factor: 0.743

Review 7.  Clinical features and management of primary biliary cirrhosis.

Authors:  Andrea Crosignani; Pier-Maria Battezzati; Pietro Invernizzi; Carlo Selmi; Elena Prina; Mauro Podda
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

Review 8.  Colchicine for prevention of cardiovascular events.

Authors:  Lars G Hemkens; Hannah Ewald; Viktoria L Gloy; Armon Arpagaus; Kelechi K Olu; Mark Nidorf; Dominik Glinz; Alain J Nordmann; Matthias Briel
Journal:  Cochrane Database Syst Rev       Date:  2016-01-27

9.  Adjuvant cholylsarcosine during ursodeoxycholic acid treatment of primary biliary cirrhosis.

Authors:  P Ricci; A F Hofmann; L R Hagey; R A Jorgensen; E Rolland Dickson; K D Lindor
Journal:  Dig Dis Sci       Date:  1998-06       Impact factor: 3.199

Review 10.  Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy.

Authors:  Treta Purohit; Mitchell S Cappell
Journal:  World J Hepatol       Date:  2015-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.